Cargando…
An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
INTRODUCTION: The aim of the study was to compare adalimumab or golimumab with infliximab in patients with moderately-to-severely active ulcerative colitis (UC). MATERIAL AND METHODS: This paper was prepared according to the PRISMA guidelines. The systematic literature search was performed in PubMed...
Autores principales: | Kawalec, Paweł, Pilc, Andrzej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016577/ https://www.ncbi.nlm.nih.gov/pubmed/27695502 http://dx.doi.org/10.5114/aoms.2016.58682 |
Ejemplares similares
-
Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013) -
Indirect costs of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. A systematic review
por: Kawalec, Paweł
Publicado: (2016) -
Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016) -
Cost-effectiveness of biological treatment of ulcerative colitis – a systematic review
por: Stawowczyk, Ewa, et al.
Publicado: (2017) -
Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland
por: Kawalec, Paweł, et al.
Publicado: (2017)